Skip to content

A Study Of Focused Shockwave For Anterior Knee Pain Following Anterior Cruciate Ligament Reconstruction

Focused Shockwave For Anterior Knee Pain Following Anterior Cruciate Ligament Reconstruction (ACL-R)

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07580157
Enrollment
20
Registered
2026-05-12
Start date
2026-08-01
Completion date
2027-12-01
Last updated
2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Cruciate Ligament Injuries

Keywords

Focused Shockwave, Bone-patellar tendon-bone autograft, Quadriceps tendon autograft

Brief summary

The purpose of this study is to investigate whether Focused Shockwave (FSW) therapy reduces anterior knee pain following anterior cruciate ligament reconstruction (ACL-R) with bone-patellar tendon-bone (BTB) or quadriceps tendon (QT) autografts.

Interventions

Focused shockwave will be administered to the autograft harvest site following anterior cruciate ligament reconstruction (ACL-R) using either bone-patellar tendon-bone (BTB) or quadriceps tendon (QT) autografts

OTHERSham Focused Shockwave

The applicator tip will be placed on the skin with sterile gel and an audio recording of the focused shockwave will be turned on to mimic the sound of the machine.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults ≥18 years of age. * Have undergone primary ACL-R with BTB or QT autograft. * Have not previously undergone FSW or radial pressure wave (RPW) in the past for any indication * Must speak English * Capacity to provide consent

Exclusion criteria

* Pregnant or breastfeeding. * Revision ACL-R. * History of previous ipsilateral knee surgery. * Multi-ligament knee injury requiring surgical intervention beyond ACL. o Not including concomitant meniscal or chondral injuries addressed at the time of surgery. * History of deep vein thrombosis. * Active infection at or near the harvest site.

Design outcomes

Primary

MeasureTime frameDescription
Change in International Knee Documentation Committee (IKDC) Subjective Knee Evaluation scoreBaseline, 7 days, 14 days, 21 days, 6 months, 9 months, and 12 monthsThe International Knee Documentation Committee (IKDC) Subjective Knee Evaluation is a patient-reported outcome measure focusing on knee symptoms, function, and sports activity. It is scored on a 0-100 scale, where higher scores indicate higher function and lower symptoms.

Secondary

MeasureTime frameDescription
Change in The Kujala Anterior Knee Pain Scale (AKPS) scoreBaseline, 7 days, 14 days, 21 days, 6 months, 9 months, and 12 monthsThe Kujala Score or Anterior Knee Pain Scale (AKPS) is a 13-item a patient-reported questionnaire that assesses subjective reactions to particular activities and symptoms that are known to correlate with anterior knee pain syndrome. The AKPS is graded on a scale of 0 to 100, with higher scores indicating better function and less pain.
Tegner activity scale scoreBaseline, 7 days, 14 days, 21 days, 6 months, 9 months, and 12 monthsThe Tegner Activity Scale (TAS) is a 2 item patient-reported questionnaire. Questions are answered with 0-10 rating system, used to standardize the measurement of work and sporting activity levels. Subjects select the highest activity level they can perform, where 0 represents disability and 10 represents national elite competitive sports.
Change in Visual Analog Scale (VAS) pain scoreBaseline, 7 days, 14 days, 21 days, 6 months, 9 months, and 12 monthsThe Visual Analog Scale (VAS) is a 1-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 10, lower scores indicating lower pain and higher scores indicating greater pain.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoshua M. Romero, M.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026